Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA ...

It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug ...

Editas Medicine Inc. (EDIT) is a clinical-stage biotechnology company involved in developing genome treatments for rare ...

Currently, no country explicitly allows heritable human genome editing in clinical settings. It is not clear to what extent ...

The CRISPR tool is capable of repairing the genetic defect responsible for the immune disease chronic granulomatous disease.

The abstract can be accessed on the ASH website here.

Spanish biotech Integra Therapeutics has upped its arsenal of gene editing tools by licensing Caszyme’s Cas12I nucleases, the ...

Yizhi “Patrick” Cai is coordinating a global effort to write a complete synthetic yeast genome. If he succeeds, the resulting cell will be the artificial life most closely related to humans to date.

ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming genetic medicines, today appointed Amy Pooler, Ph.D., as Senior Vice President, Research ...

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the third quarter 2024 and ...